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Complications of eosinophilic esophagitis (EoE) include esophageal fibrosis, esophageal 
stricture and progressive esophageal dysfunction that can manifest as symptoms of 
dysphagia, pain, and recurrent food impaction1. As the prevalence of EoE continues to rise 
and since tissue remodeling persists in some patients after treatment-induced resolution of 
acute inflammation, a clear need exists to understand underlying pathophysiologic 
mechanisms responsible for stricture formation in order to identify novel therapeutic targets.
Although a number of Th2 cytokines are considered to play a role in EoE, an increasing 
body of evidence supports a key role for TGF-β in stimulating remodeling effects in a 
number of different esophageal cells. For instance, TGF-β has been shown to induce 
epithelial-mesenchymal transition (EMT), smooth muscle contractility and fibroblast 
activation2-6. In addition, as highlighted by Muir et al in this issue of JPGN, tissue 
distensibility may also be affected and may be a functional target as evidenced by its 
extracellular matrix composition and effect on cellular substrate rigidity.
The authors seek to further expand our understanding of the mechanical and chemical 
microenvironmental impact in EoE by studying TGF-β's effects on substrate rigidity as it 
relates to human esophageal fibroblasts. They hypothesized that the fibroblasts from 
pediatric patients may respond differently to TGF-β compared to those from adults. Results 
could explain the clinical finding that fibrostenosis is a progressive problem that is more 
evident in adults than children.
To begin to address this, the authors use two innovative ex vivo model systems including 
polyacrylamide gel-based platforms with variable stiffness as well as a novel 
microfabricated-Post-Array- Detectors (m 266 PADs) system. Together these models 
provide a novel opportunity to measure differences in TGF-β induced remodeling in 
pediatric and adult fibroblasts.
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Their results show that in a microenvironment rich with TGF-β, human esophageal 
fibroblasts exhibit increased activation, fibrogenesis and contraction and that fibroblast 
activation and the in situ stiffness of the fibroblast environment may critically influence or 
perpetuate TGF-β signaling. Muir et al highlight how matrix stiffness may influence 
fibroblast activity in specific disease-associated microenvironments.
They also address the global concept that esophageal fibroblast behavior changes with aging 
and maturation. For instance, similar TGF- β pro-fibrotic responses were measured in 
fibroblasts obtained from children and adults subjects without EoE. In contrast, fibroblasts 
obtained from adults with active EoE responded with greater Type I Collagen synthesis than 
pediatric EoE fibroblasts. Together these results suggest a developmental paradigm specific 
to both age and inflammation. Fibroblasts may respond to fibrogenic agonists in a 
differential manner following inflammatory processes depending on their age and duration 
of disease activity. Clinically, this finding could explain the perceived propensity for 
strictures and fibrostenosis to develop more often in adults than in children.
These provocative findings also leave us with some unanswered questions. Is this paradigm 
true for all patients? Certainly, clinical experiences suggest that some pediatric patients may 
develop strictures whereas some adults with EoE may not. Is this clinical observation related 
to a genetic predisposition to develop strictures (i.e. fibrostenotic EoE) or a variable 
expression of TGF-β and its receptors within the tissue microenvironment? Comparisons of 
fibroblast stiffness from both pediatric and adult patients with well-defined fibrostenotic 
disease and non-stricturing disease may help us understand this conundrum. What is the 
source of TGF-β? Since some non-inflamed tissues may continue to exhibit fibrostenosis, it 
is suggested that TGF-β may be stored within the matrix and be released depending on tissue 
stiffness. This may be true, but the biologic activity of the TGF-β in this circumstance is 
unknown and TGF-β can be synthesized and released by a number of cells including mast 
cells and eosinophils that may have escaped mucosal biopsy detection. Is fibrosis inevitable 
in all EoE patients despite successful anti-inflammatory treatments? Can this be a reflection 
of the persistence of tissue remodeling in some patients after treatment-induced resolution of 
inflammation. Finally, are there therapeutic interventions that may target TGF-β and not 
eosinophils? Interestingly, a recent study identified TGF-β as a novel therapeutic target in 
children with EoE and connective tissue diseases 7. Their findings support the need for early 
detection and chronic treatment of this disease.
The authors' findings set the stage for a number of future studies. In addition, they introduce 
us to important novel technologies that may provide insights for in vitro and ex vivo EoE 
models and sheds new light on the potential role of TGF-β in EoE remodeling. Ex vivo 
modeling provides us with some insights into processes that may be occurring in the sub-
epithelial layer, an area inconsistently captured by mucosal biopsies, but one in which 
clinical decisions are often based upon. For instance, lamina propria fibrosis is not 
infrequently used as an indicator of chronicity or pathological fibrosis. Findings presented 
here suggest that both control and EoE fibroblasts responded similarly to TGF-β with respect 
to SMA, fibronectin, collagen 1a, and indicate that fibrosis may be a common finding related 
to mucosal injury but not to a specific disease state.
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Clinical implications of this study relate to age-associated changes in esophageal fibroblast 
function. Development of fibrosis and increased tissue stiffness may perpetuate further tissue 
remodeling and thus explain disease progression. These results highlight the importance of 
early functional assessment of the esophagus with techniques such as manometry or the 
EndoFLIP (Endolumenal Functional Lumen Imaging Probe), a catheter-based technology 
that can determine esophageal distensibility as a measure of compliance in both children and 
adults. The clinical identification of earlier evidence of tissue rigidity may be an important 
opportunity for therapeutic intervention and the prevention of constitutive fibroblast 
activation that may be independent of inflammatory stimulus, as is presented in this study. 
Therapeutic studies targeting TGF-β provide novel approaches to caring for some patients 
(https://www.clinicaltrials.gov/ct2/show/NCT01808196). As our understanding of tissue 
remodeling and fibrosis increases, natural history studies (http://
www.rarediseasesnetwork.org/cms/cegir/) and those extending beyond the mucosal pinch 
biopsy that involve the complex interactions among eosinophils, fibroblasts and other cell 
types involved in tissue remodeling are vital.
 Acknowledgments
Supported by: NIH 1K24DK100303 (Furuta GT) and Consortium for Gastrointestinal Eosinophilic Researchers 
(CEGIR). CEGIR (U54 AI117804) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative 
of the Office of Rare Diseases Research (ORDR), NCATS, and is funded through collaboration between NIAID, 
NIDDK, and NCATS (GTF), APFED (GTF, JCM), and NIH 1K01DK106315 (JCM).
References
1. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus 
recommendations for children and adults. J Allergy Clin Immunol. 2011; 128:3–20 e6. [PubMed: 
21477849] 
2. Kagalwalla AF, Akhtar N, Woodruff SA, et al. Eosinophilic esophagitis: epithelial mesenchymal 
transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin 
Immunol. 2012; 129:1387–96 e7. [PubMed: 22465212] 
3. Rieder F, Nonevski I, Ma J, et al. T-helper 2 cytokines, transforming growth factor beta1, and 
eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic 
esophagitis. Gastroenterology. 2014; 146:1266–77 e1-9. [PubMed: 24486052] 
4. Aceves SS, Chen D, Newbury RO, Dohil R, Bastian JF, Broide DH. Mast cells infiltrate the 
esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-beta1, and 
increase esophageal smooth muscle contraction. J Allergy Clin Immunol. 2010; 126:1198–204 e4. 
[PubMed: 21047675] 
5. Muir AB, Dods K, Noah Y, et al. Esophageal epithelial cells acquire functional characteristics of 
activated myofibroblasts after undergoing an epithelial to mesenchymal transition. Experimental cell 
research. 2015; 330:102–10. [PubMed: 25183431] 
6. Tkachenko E, Rawson R, La E, et al. Rigid substrate induces esophageal smooth muscle 
hypertrophy and eosinophilic esophagitis fibrotic gene expression. J Allergy Clin Immunol. 2015
7. Abonia JP, Wen T, Stucke EM, et al. High prevalence of eosinophilic esophagitis in patients with 
inherited connective tissue disorders. J Allergy Clin Immunol. 2013; 132:378–86. [PubMed: 
23608731] 
Nguyen et al. Page 3
J Pediatr Gastroenterol Nutr. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
